# US 2019/0315711 A1 · Therapeutic compounds and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315711 A1
- Document ID: US20190315711A1
- Status: Published application
- Kind: A1
- Application number: 16/471,942
- Filed: 2017-12-15
- Published: 2019-10-17
- Earliest claimed: 2016-12-23
- Applicants: eXIthera Pharmaceuticals, Inc.
- Inventors: Bertrand L. Chenard; Yuelian Xu; Frans L. Stassen; Neil J. Hayward
- Web page: https://patentgrep.com/patent/US20190315711A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/14: containing three or more hetero rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

## Claims

### Claim 1

A compound of formula (I-1):
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen or —NR8R9;
Ra is C1-6 alkyl, C1-6 haloalkyl, halo, cyano, or —OR6;
Rb is hydrogen or C1-6 alkyl;
R2 is C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or —OR6, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one, two, or three independent occurrences of halo, C1-6 alkyl, C1-6 haloalkyl, or —OR6;
R3 is hydrogen, C1-6 alkyl, or C1-6 haloalkyl, or
R2 and R3, taken together with the nitrogen atom to which they are attached form a ring (e.g., a 3-10 membered ring);
R4 is C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one, two, or three independent occurrences of halo, C1-6 alkyl, C1-6 haloalkyl, cyano, or —OR6;
R5 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, or aryl, wherein the cycloalkyl or aryl is optionally substituted with one, two, or three independent occurrences of halo, C1-6 alkyl, C1-6 haloalkyl, or —OR6 or
R4 and R5, taken together with the carbon atom to which they are attached form a ring;
R6 is hydrogen, C1-6 alkyl, or C1-6 haloalkyl;
each R8 and R9 is independently hydrogen C1-6 alkyl, —C(O)R10, or —C(O)OR10;
R10 is C1-6 alkyl or C1-6 haloalkyl;
m is 0, 1, 2, or, 3; and
n is 0 or 1, wherein if n is 0, then R5 is hydrogen and R4 is absent.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula (I):

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein R6 is C1-6 alkyl or C1-6 haloalkyl.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen, —NH2, or —NHCH3.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Ra is —C1-6 alkyl.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, aryl, heteroaryl, or —OR6, wherein the cycloalkyl, aryl, or heteroaryl is optionally substituted with one, two, or three independent occurrences of halo, C1-6 alkyl, C1-6 haloalkyl, or —OR6.

### Claim at position 12

12-14. (canceled)

### Claim 15 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen, —CH3, or —CH2CH3.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein R4 is cycloalkyl, aryl, or heteroaryl, wherein the cycloalkyl, aryl, or heteroaryl is optionally substituted with one, two, or three independent occurrences of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, or —OR6.

### Claim at position 17

19-22. (canceled)

### Claim 23 (depends on 1)

The compound of claim 1, wherein R5 is hydrogen, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, cyclopropyl, phenyl, or —CF3, wherein the cyclopropyl or phenyl is optionally substituted with one, two, or three independent occurrences of halo, C1-6 alkyl, C1-6 haloalkyl, cyano, or —OR6.

### Claim at position 19

24-27. (canceled)

### Claim 28 (depends on 1)

The compound of claim 1, wherein m is 1.

### Claim at position 21

29-31. (canceled)

### Claim 32 (depends on 1)

The compound of claim 1, wherein the compound is a compound of formula (I-e), formula (I-f), formula (I-g), formula (I-h), formula (I-i), or formula (I-j):
wherein R4 is C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one, two, or three independent occurrences of halo, C1-6 alkyl, C1-6 haloalkyl, cyano, or —OR6;
each of Rb and Rc is independently halo, C1-6 alkyl, C1-6 haloalkyl, cyano, or —OR6; and
each of p and q is independently 0, 1, 2, or 3.

### Claim 33

A compound of the formula:

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I-1) according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

### Claim at position 26

36-60. (canceled)

### Claim 61 (depends on 1)

A method of inhibiting Factor XIa in a subject, comprising administering to a subject that has suffered ischemia an effective amount of a compound of formula (I-1) according to claim 1.

### Claim at position 28

62-64. (canceled)

### Claim 65 (depends on 1)

A method of treating a thromboembolic consequence or complication in a subject, comprising administering to a subject an effective amount of a compound of formula (I-1) according to claim 1.

### Claim 66 (depends on 65)

The method of claim 65, wherein the thromboembolic consequence or complication is associated with a peripheral vascular intervention, hemodialysis, catheter ablation, a cerebrovascular intervention, transplantation of an organ, surgery, a trans-catheter aeortic valve implantation, a large bore intervention used to treat an aneurysm, a percutaneous coronary intervention, or hemophilia therapy.

### Claim at position 31

67-128. (canceled)

### Claim 129 (depends on 65)

The method of any one of claim 65, wherein the compound is administered orally or parenterally.

### Claim 130 (depends on 65)

The method of any one of claim 65, wherein the compound is administered orally.

### Claim at position 34

131-134. (canceled)

### Claim 135 (depends on 65)

The method of any one of claim 65, wherein the subject is a human.

### Claim 136

A pharmaceutically acceptable salt of a compound of the formula:
